Y90 Radioembolization for Early Kidney Cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a treatment called Y90 radioembolization for people with early-stage kidney cancer who cannot have surgery or ablation. Tiny radioactive beads are delivered through a catheter to the tumor's blood supply to destroy it from the inside.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage T1 or T2a kidney cancer that has not spread to lymph nodes or other organs.
- You have 1 or 2 solid tumors in one kidney (at least 80% solid).
- You and your doctor have decided that surgery or heat/cold ablation is not the best option for you.
- Your kidney function is adequate (GFR 45 or higher).
- You are generally well enough to do daily activities (ECOG 0 or 1).
- You have not had radiation to your abdomen before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a procedure called Y-90 radioembolization for patients with kidney cancer tumors larger than 4 cm who cannot have or choose not to have surgery. The treatment delivers tiny radioactive beads through a blood vessel to the tumor to destroy cancer cells while limiting damage to healthy tissue.
This trial tests a treatment called yttrium-90 radioembolization (tiny radioactive beads delivered to the liver) for people with liver cancer that has already been treated before. The goal is to see if it can help control the tumor when other treatments haven't been enough.
This study looks at how well Y90 “radioembolization” treatment delivers radiation and how much radiation reaches your body. If you can safely get extra PET/CT scans and blood tests around your treatment, you may be invited to participate.
This study tests a higher dose of radiation delivered directly to liver tumors through small beads. It aims to improve tumor control while keeping side effects manageable for people whose liver cancer is not removable by surgery.
This trial tests a treatment called radioembolization (yttrium-90) given before surgery for colorectal cancer that has spread to the liver. It aims to shrink the liver tumors so that surgery becomes safer and more effective, and it also looks at immune markers and dosimetry to personalize the treatment.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
Hear when a new Stage I Renal Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.